June 9, 2016
Takeda Pharmaceutical and Ultragenyx Pharmaceutical have forged a strategic partnership to develop and commercialize therapies for rare genetic diseases, with the pair set to license each other’s pipelines and Takeda investing up to US$65 million in the US biotech, the...read more